Literature DB >> 32682839

On-Label and Off-Label Clinical Studies of FDA-Approved Ophthalmic Therapeutics.

Anand D Gopal1, Joshua D Wallach2, Saloni A Shah3, Carl Regillo4, Joseph S Ross5.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32682839     DOI： 10.1016/j.ophtha.2020.07.028

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  2 in total

1.  Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy.

Authors:  Julianna E Murray; Aaron S Gold; Azeema Latiff; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2021-12-18

2.  The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.

Authors:  Magdalena Musiał-Kopiejka; Katarzyna Polanowska; Dariusz Dobrowolski; Katarzyna Krysik; Edward Wylęgała; Beniamin Oskar Grabarek; Anita Lyssek-Boroń
Journal:  Int J Environ Res Public Health       Date:  2022-02-17       Impact factor: 3.390
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.